Scientific journal
Научное обозрение. Медицинские науки
ISSN 2500-0780
ПИ №ФС77-57452

Personal portfolio

CLINICAL EVALUATION OF ANTI-TUMOR EFFICACY SUBTHERAPEUTIC DOSES OF METOTREXATE, ENDOLYMPHATIC IMPOSED

Rozenko L.Y. 1 Frantsiyants E.M. 1 Dzhabarov F.R. 1
1 Federal State Institution «Rostov Cancer Research Institute» of the Ministry of Health of the Russian Federation
The analysis of a 3 comparable groups of patients with cervical cancer T3NхMo. The control group (29 people) received a standard combined radiotherapy. 37 patients before exposure to regional lymph vessels entered twice at weekly intervals for 25 ± 5 mg methotrexate and 2000 ± 400 mg cyclophosphamide. 29 women endolymphatic introduced only 5 mg of methotrexate. The total effect of controlled regression in the first 2 weeks of treatment was equivalent, respectively – 51,7; 70,3 and 65,5% of cases. Remote 5-year survival with subtherapeutic doses of methotrexate was significantly higher compared with the control 68,4 ± 6,7% vs 48,3 ± 7,1% (p <0,05) and equivalent to 62,8 ± 6,8% in the endolymphatic high doses of cytostatics. Mechanism of anti-tumor effect of subtherapeutic doses of cytostatic agents imposed lymph path, requires further examination.